false 0001174940 0001174940 2024-10-18 2024-10-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934.

 

Date of Report: October 18, 2024

(Date of earliest event reported)

 

Oragenics, Inc.

(Exact name of registrant as specified in its charter)

 

FL   001-32188   59-3410522

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification Number)

 

1990 Main Street

Suite 750

Sarasota, FL

   34236
(Address of principal executive offices)   (Zip Code)

 

813-286-7900

(Registrant’s telephone number, including area code)

 

 

(Former Name or Former Address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   OGEN   NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 7.01 Regulation RD Disclosure.

 

Oragenics, Inc. (“Oragenics” or the “Company”) announced that the Company’s President, Michael Redmond, will be presenting at The Centurion One Capital 2nd Annual Bahamas Summit on Tuesday, October 22, 2024. A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

 

The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit

No.

  

Description

   
99.1   Press Release.
     
104   Cover page Interactive Data File (embedded in the cover page formatted in Inline XBRL)

 

 

 

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this October 18, 2024.

 

 

ORAGENICS, INC.

(Registrant)

   
  BY: /s/ Janet Huffman
   

Janet Huffman

Chief Financial Officer

 

 

 

Exhibit 99.1

 

Oragenics Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

 

 

Sarasota, FL – October 18, 2024 – Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments for brain-related health conditions, announced it will be presenting at the Centurion One Capital 2nd Annual Bahamas Summit to be held at the Rosewood Baha Mar Hotel on October 22-23, 2024, in Nassau, Bahamas. Michael Redmond, President of Oragenics, will participate in a corporate presentation and Q&A session on October 22, 2024 at 1:20 pm ET.

 

Details for the presentation are as follows:

 

Date: Tuesday, October 22, 2024

 

Time: 1:20 p.m. EDT

 

Presenter: Michael Redmond, President of Oragenics

 

Register for the event by clicking here.

 

About Oragenics:

 

Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as well as proprietary powder formulation and an intranasal delivery device. For more information, please visit www.oragenics.com.

 

Investor Relations:

 

Rich Cockrell

CG Capital

404-736-3838

ogen@cg.capital

 

 

 

v3.24.3
Cover
Oct. 18, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 18, 2024
Entity File Number 001-32188
Entity Registrant Name Oragenics, Inc.
Entity Central Index Key 0001174940
Entity Tax Identification Number 59-3410522
Entity Incorporation, State or Country Code FL
Entity Address, Address Line One 1990 Main Street
Entity Address, Address Line Two Suite 750
Entity Address, City or Town Sarasota
Entity Address, State or Province FL
Entity Address, Postal Zip Code 34236
City Area Code 813
Local Phone Number 286-7900
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol OGEN
Security Exchange Name NYSEAMER
Entity Emerging Growth Company false
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Oragenics Charts.
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Oragenics Charts.